Provider of Quality Medical Diagnostic & Research Products

RSS

News

Development of an individual Anti-FVIII Inhibitors ELISA to improve Haemophiliacs therapeutic follow up Peyrafitte M.1, Vissac A.M.1, Amiral J.2 1HYPHEN BioMed, Research, Neuville sur Oise, France. 2HYPHEN BioMed, Neuville sur Oise, France
The multiple faces of tissue factor measured with laboratory assays Laroche M.1, Peyrafitte M.1, Vissac A.M.1, Amiral J.2 1HYPHEN BioMed, Research, Neuville sur Oise, 2HYPHEN BioMed, Neuville sur Oise, France
Microparticles exposing Tissue Factor in human plasma Laroche M.1, Vissac A.M.1, Peyrafitte M.1, Amiral J.2 1HYPHEN BioMed, Research, Neuville sur Oise, France 2HYPHEN BioMed, Neuville sur Oise, France
We had our usual space at this annual meeting and managed to sit in on some excellent presentations.
Modern anticoagulants threaten status quo. Could the shift towards first-in-class novel oral treatments, which are expected to prove beneficial for prevention of stroke caused by AF, render warfarin obselete?
Quadratech are liaising with our couriers ‘Wey Group International’ to minimise the disruption caused by the London 2012 Olympics.
Quadratech will be exhibiting at or attending the following meetings in 2012
2011 is a landmark year for Quadratech as it is our 20th Birthday. The company was founded in 1991 and has continued to grow and thrive over the intervening years, to the company you know today.
MICROPARTICLES MEETING -11 October 2011
In September 2010 amongst the dreaming spires of Oxford's Magdalen College the topic of 'Micro and Nanovesicles in Health and Disease' was explored.
The NEQAS Blood Coagulation Annual Scientific Meeting, held in Sheffield on 8th and 9th September 2010, was as usual very well attended and received.